Troglitazone (Rezulin, Resulin, Romozin, Noscal) is an antidiabetic and anti-
inflammatory drug, and a member of the drug class of the thiazolidinediones.
During all clinical studies in North America, a total of 48 of 2510 (1.9%) Rezulin (
troglitazone removed from the us market 3/21/00) -treated patients and 3 of 475 ...
BACKGROUND: Troglitazone was removed from the U.S. market because its use
was associated with an increased risk of liver failure. We evaluated the clinical ...
Troglitazone was the first thiazolidinedione antidiabetic agent approved for
clinical use in 1997, but it was withdrawn from the market in 2000 due to serious
Jun 13, 2005 ... Troglitazone is not chemically or functionally related to either the sulfonylureas,
the biguanides, or the g-glucosidase inhibitors. Troglitazone ...
Troglitazone, a peroxisome proliferator–activated receptor gamma agonist, which
enhances insulin sensitivity, was approved for the treatment of type 2 diabetes ...
Troglitazone is an oral antihyperglycemic agent which acts primarily by
decreasing insulin resistance. Troglitazone is used in the management of type II
EDITORIALS. Insight Into Hepatotoxicity: The Troglitazone. Experience. See
Article on Page 237. Troglitazone entered the U.S. market in 1997 as the first
FDA Endocrine and Metabolic Drugs Advisory Committee Meeting on
Troglitazone. The last time I appeared before this advisory committee to present ...
Resulin™. Troglitazone is a TZD which was approved for the treatment of insulin
resistance and hyperglycemia in Type II diabetes, under the trade name ...